- US-listed companies
- Nuvectis Pharma, Inc.
Nuvectis Pharma, Inc.NVCT
Market cap
$108.39M
P/E ratio
Dec 31, 2022 | Dec 31, 2023 | |
Research and development | 13 | 15 |
General and administrative | 6 | 8 |
OPERATING LOSS | -19 | -23 |
Finance income | 0 | 1 |
NET LOSS | -19 | -22 |
NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS | -19 | -22 |
Earnings Per Share, Basic | -1.51 | -1.43 |
Earnings Per Share, Diluted | -1.51 | -1.43 |